Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.48 |
| ▸ | BCHE | P06276 | 5/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 5/20 | 0.37 |
| ▸ | DRD2 | P14416 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23876655 | 0.76 | SRD5A1 (0.40) | ACHEBCHESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3090108 | 0.75 | MAPT (0.50) | ACHESLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL3090113 | 0.75 | MAPT (0.50) | ACHESLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL7346460 | 0.75 | ACHE (0.48) | ACHEBCHE | |
| SCHEMBL23876652 | 0.73 | ACHE (0.38) | ACHESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12371994 | 0.72 | SIGMAR1 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3816582 | 0.70 | ACHE (0.47) | ACHEBCHE | |
| SCHEMBL3816577 | 0.70 | ACHE (0.47) | ACHEBCHE | |
| SCHEMBL23876656 | 0.70 | ADRA1B (0.38) | ACHEBCHESLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL52235 | 0.69 | ACHE (0.46) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192886-B2 | S1P1 agonist and application thereof | MEDSHINE DISCOVERY INC. (CN) | 2021-12-07 | — | — | US | disclosed |
| US-20210300908-A1 | S1P1 AGONIST AND APPLICATION THEREOF | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2021-09-30 | — | — | US | disclosed |
| EP-3492465-A1 | S1P1 AGONIST AND APPLICATION THEREOF | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192886-B2 | S1P1 agonist and application thereof | S1PR1, S1PR2, S1PR3 | ACHE 4137/4885BCHE 3940/4885SLC6A2 285/4885 |
| US-20210300908-A1 | S1P1 AGONIST AND APPLICATION THEREOF | S1PR1, S1PR2, S1PR3 | ACHE 4137/4885BCHE 3940/4885SLC6A2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.